| Literature DB >> 10532100 |
S I Moiseev1, K M Abdulkadyrov, L N Bubnova, T V Glazanova, O E Rozanova, I E Pavlova, V A Balashova, A L Kovalenko.
Abstract
The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10532100
Source DB: PubMed Journal: Vopr Onkol ISSN： 0507-3758